(-?)?-Maackiain
Based on 1 Customer Validation
(-)-Maackiain is a pterocarpan phytoalexin produced from Sophora flavescens. (-)-Maackiain is toxic to several genera of fungal pathogens of legume and non legume hosts. (-)-Maackiain enhances the activation of NLRP3 inflammasome, inhibits the activation of NF-κB pathway, exhibiting thereby immunostimulatory and anti-inflammatory activities. (-)-Maackiain is orally active.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.50%
- CAS 番号: 2035-15-6
- 分子式: C16H12O5
- 分子量:284.27
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-15 | IC50 |
>25 μg/mL
Compound: 6
|
Cytotoxicity against human HCT15 cells by MTT assay
Cytotoxicity against human HCT15 cells by MTT assay
|
[PMID: 17764956] |
| HL-60 | IC50 |
17.9 μg/mL
Compound: 6
|
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
|
[PMID: 17764956] |
| HMC1 | IC50 |
>20 μM
Compound: 9
|
Cytotoxicity against human HMC1 cells assessed as cell viability
Cytotoxicity against human HMC1 cells assessed as cell viability
|
[PMID: 25467151] |
| HMC1 | IC50 |
3.01 μM
Compound: 9
|
Inhibition of A23187-induced IL-6 production in human HMC1 cells incubated for 30 mins prior to A23187 challenge measured after 24 hrs by ELISA
Inhibition of A23187-induced IL-6 production in human HMC1 cells incubated for 30 mins prior to A23187 challenge measured after 24 hrs by ELISA
|
[PMID: 25467151] |
| MDA-MB-435 | IC50 |
11.5 μg/mL
Compound: 6
|
Cytotoxicity against human MDA-MB-435 cells by MTT assay
Cytotoxicity against human MDA-MB-435 cells by MTT assay
|
[PMID: 17764956] |
| RAW264.7 | IC50 |
27 μM
Compound: 2
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
|
[PMID: 25592708] |
| U-937 | IC50 |
>100 μM
Compound: 19, l-maackiain
|
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
|
[PMID: 17158054] |
| U-937 | IC50 |
>100 μM
Compound: 19, l-maackiain
|
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
|
[PMID: 17158054] |
| U-937 | IC50 |
>100 μM
Compound: 19, l-maackiain
|
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
|
[PMID: 17158054] |
(-)-Maackiain (0-30 µM, 24 h) inhibits PMA (HY-18739)-induced histamine H1 receptor (H1R) expression in HeLa cells, inhibits DNP-HSA (antigen)-stimulated IL-4 gene expression in RBL-2H3 cells[3].
(-)-Maackiain (0-30 µM, 24 h) inhibits PMA -induced PKCδ phosphorylation at tyrosine 311 and prevents PKCδ from transferring to the Golgi apparatus[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa, RBL-2H3
-
Concentration:0-30 µM
-
Incubation Time:24 h
-
Result:Inhibited the mRNA expression of H1R and IL-4.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:TDI-induced nasal hypersensitivity mouse model[3]
-
Dosage:5-20 mg/kg
-
Administration:po, once daily for 3 weeks
-
Result:Reduced sneezing, nasal mucosal swelling, redness and watery rhinorrhea.
化学情報
-
CAS 番号 2035-15-6
-
性状 Solid
-
分子量 284.27
-
分子式 C16H12O5
-
Color White to light yellow
-
SMILES
OC1=CC=C([C@@]2([H])[C@@](C3=C(C=C4C(OCO4)=C3)O2)([H])CO5)C5=C1
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
DMSO : 100 mg/mL (351.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (274 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[2]. Huh JW, et al., Maackiain, a compound derived from Sophora flavescens, increases IL-1β production by amplifying nigericin-mediated inflammasome activation. FEBS Open Bio. 2020 Aug;10(8):1482-1491. [Content Brief]
[3]. Mizuguchi H, et al., Maackiain is a novel antiallergic compound that suppresses transcriptional upregulation of the histamine H1 receptor and interleukin-4 genes. Pharmacol Res Perspect. 2015 Oct;3(5):e00166. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5178 mL | 17.5889 mL | 35.1778 mL | 87.9446 mL |
| 5 mM | 0.7036 mL | 3.5178 mL | 7.0356 mL | 17.5889 mL | |
| 10 mM | 0.3518 mL | 1.7589 mL | 3.5178 mL | 8.7945 mL | |
| 15 mM | 0.2345 mL | 1.1726 mL | 2.3452 mL | 5.8630 mL | |
| 20 mM | 0.1759 mL | 0.8794 mL | 1.7589 mL | 4.3972 mL | |
| 25 mM | 0.1407 mL | 0.7036 mL | 1.4071 mL | 3.5178 mL | |
| 30 mM | 0.1173 mL | 0.5863 mL | 1.1726 mL | 2.9315 mL | |
| 40 mM | 0.0879 mL | 0.4397 mL | 0.8794 mL | 2.1986 mL | |
| 50 mM | 0.0704 mL | 0.3518 mL | 0.7036 mL | 1.7589 mL | |
| 60 mM | 0.0586 mL | 0.2931 mL | 0.5863 mL | 1.4657 mL | |
| 80 mM | 0.0440 mL | 0.2199 mL | 0.4397 mL | 1.0993 mL | |
| 100 mM | 0.0352 mL | 0.1759 mL | 0.3518 mL | 0.8794 mL |
(-)-Maackiain 関連分類
HY-N6051 関連分類
Powered by Bioz